Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-03

AUTHORS

Udo Holtick, Marco Herling, Natali Pflug, Geothy Chakupurakal, Silke Leitzke, Dominik Wolf, Michael Hallek, Christof Scheid, Jens M. Chemnitz

ABSTRACT

The fludarabine, amsacrine, and cytarabine (FLAMSA)-reduced-intensity conditioning (RIC) protocol has been described to be effective in patients with high-risk and refractory acute myeloic leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (aSCT). To increase safety and tolerability of the conditioning, we previously reported the feasibility to substitute the TBI component by treosulfan in elderly AML patients. We now present long-term follow-up data on patients treated with FLAMSA/treosulfan compared to the original FLAMSA/4Gy TBI protocol. We retrospectively analyzed 130 consecutive patients with high-risk or relapsed AML after aSCT following FLAMSA conditioning at our center. Fifty-eight patients were treated with FLAMSA/treosulfan due to age and/or comorbidities. Seventy-two patients were treated with FLAMSA/TBI. Median age of patients treated with FLAMSA/treosulfan was 60 years compared to 46 years in those treated with FLAMSA/TBI. The cumulative incidence of a non-relapse mortality at 4 years was 28% in FLAMSA/treosulfan patients as compared to 13% in FLAMSA/TBI. Cumulative incidence of relapse was higher in patients treated with FLAMSA/TBI (46 vs. 32%). This difference was even more prominent for patients treated in blast persistence prior to transplant (relapse incidence 70% for TBI vs. 35% for treosulfan). The overall and relapse-free survival rates at 4 years were 47 and 41%, respectively, for patients treated with FLAMSA/TBI as compared to 43 and 40% in patients treated with FLAMSA/treosulfan. These data indicate an anti-leukemic activity by FLAMSA/treosulfan especially in patients with a blast persistence prior to transplant. Older age was an independent factor for a higher non-relapse mortality. Translating FLAMSA/treosulfan to younger patients, a lower non-relapse mortality, and an improved anti-leukemic activity might add up to improved overall survival. Randomized studies are required to demonstrate an improved efficacy of treosulfan- versus TBI-based FLAMSA conditioning. More... »

PAGES

479-487

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-016-2887-4

DOI

http://dx.doi.org/10.1007/s00277-016-2887-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007456209

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27909887


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Alkylating", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Busulfan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation Conditioning", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation, Homologous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Whole-Body Irradiation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holtick", 
        "givenName": "Udo", 
        "id": "sg:person.01060152106.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060152106.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Herling", 
        "givenName": "Marco", 
        "id": "sg:person.01046626565.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046626565.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pflug", 
        "givenName": "Natali", 
        "id": "sg:person.0775410503.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775410503.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chakupurakal", 
        "givenName": "Geothy", 
        "id": "sg:person.0776253454.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776253454.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Leitzke", 
        "givenName": "Silke", 
        "id": "sg:person.01167664514.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167664514.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Bonn", 
          "id": "https://www.grid.ac/institutes/grid.10388.32", 
          "name": [
            "Department III of Internal Medicine, University of Bonn, Bonn, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolf", 
        "givenName": "Dominik", 
        "id": "sg:person.014553451012.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014553451012.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hallek", 
        "givenName": "Michael", 
        "id": "sg:person.01025161256.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025161256.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scheid", 
        "givenName": "Christof", 
        "id": "sg:person.01312015730.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312015730.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cologne", 
          "id": "https://www.grid.ac/institutes/grid.6190.e", 
          "name": [
            "BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50924, K\u00f6ln, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chemnitz", 
        "givenName": "Jens M.", 
        "id": "sg:person.01126003571.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126003571.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bmt.2015.297", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000925323", 
          "https://doi.org/10.1038/bmt.2015.297"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2005-10-4165", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002613179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-015-2349-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005008575", 
          "https://doi.org/10.1007/s00277-015-2349-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/10428190701671051", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006880760"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.1993.03510010063030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008473572"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2002-11-3615", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008819249"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.62.7273", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016119976"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.48.8114", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018190408"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2012.070235", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025546715"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.3429", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026375599"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2005-05-2004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027035706"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/ejh.12615", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031702566"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2003-03-0855", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034662194"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1705965", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035841647", 
          "https://doi.org/10.1038/sj.bmt.1705965"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2013.185", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036134746", 
          "https://doi.org/10.1038/bmt.2013.185"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-011-1253-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037372318", 
          "https://doi.org/10.1007/s00277-011-1253-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/moh.0b013e3283309647", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044469666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/moh.0b013e3283309647", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044469666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/moh.0b013e3283309647", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044469666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.07.061", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044565530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1704784", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050128567", 
          "https://doi.org/10.1038/sj.bmt.1704784"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2141.2000.02196.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056733260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/10245330701214285", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058358190"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.12.049", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203203"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076834181", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1988.6.10.1562", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079525316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083204471", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-03", 
    "datePublishedReg": "2017-03-01", 
    "description": "The fludarabine, amsacrine, and cytarabine (FLAMSA)-reduced-intensity conditioning (RIC) protocol has been described to be effective in patients with high-risk and refractory acute myeloic leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (aSCT). To increase safety and tolerability of the conditioning, we previously reported the feasibility to substitute the TBI component by treosulfan in elderly AML patients. We now present long-term follow-up data on patients treated with FLAMSA/treosulfan compared to the original FLAMSA/4Gy TBI protocol. We retrospectively analyzed 130 consecutive patients with high-risk or relapsed AML after aSCT following FLAMSA conditioning at our center. Fifty-eight patients were treated with FLAMSA/treosulfan due to age and/or comorbidities. Seventy-two patients were treated with FLAMSA/TBI. Median age of patients treated with FLAMSA/treosulfan was 60\u00a0years compared to 46\u00a0years in those treated with FLAMSA/TBI. The cumulative incidence of a non-relapse mortality at 4\u00a0years was 28% in FLAMSA/treosulfan patients as compared to 13% in FLAMSA/TBI. Cumulative incidence of relapse was higher in patients treated with FLAMSA/TBI (46 vs. 32%). This difference was even more prominent for patients treated in blast persistence prior to transplant (relapse incidence 70% for TBI vs. 35% for treosulfan). The overall and relapse-free survival rates at 4\u00a0years were 47 and 41%, respectively, for patients treated with FLAMSA/TBI as compared to 43 and 40% in patients treated with FLAMSA/treosulfan. These data indicate an anti-leukemic activity by FLAMSA/treosulfan especially in patients with a blast persistence prior to transplant. Older age was an independent factor for a higher non-relapse mortality. Translating FLAMSA/treosulfan to younger patients, a lower non-relapse mortality, and an improved anti-leukemic activity might add up to improved overall survival. Randomized studies are required to demonstrate an improved efficacy of treosulfan- versus TBI-based FLAMSA conditioning.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00277-016-2887-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1018247", 
        "issn": [
          "1269-3286", 
          "1279-8509"
        ], 
        "name": "Annals of Hematology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "96"
      }
    ], 
    "name": "Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML", 
    "pagination": "479-487", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2383efb33993cdb76c2494692526325dd4575e739d3e99675078080540a7e675"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27909887"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9107334"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-016-2887-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007456209"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-016-2887-4", 
      "https://app.dimensions.ai/details/publication/pub.1007456209"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000362_0000000362/records_87100_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00277-016-2887-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-016-2887-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-016-2887-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-016-2887-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-016-2887-4'


 

This table displays all metadata directly associated to this object as RDF triples.

279 TRIPLES      21 PREDICATES      72 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-016-2887-4 schema:about N0464975e77fe4ea6ac7076d3aadaf442
2 N058320180603484c8cde9a5d3bcade26
3 N0909d8428c784616a553a25987db0184
4 N0c3763d7446b4e9b884646cba85ced89
5 N11e810deffa74474a1700f67065adb01
6 N34c72d37052d41e4a6493bd52cbd3891
7 N3e480aa999424ee090aa8b5d5bbb5884
8 N3ebfaf3943544722951328981cbc74bb
9 N46922b729f294be393912753ae1336bd
10 N4d421574c4114defb87e73f88aae0f70
11 N5000720823d24080a2c8c44b78ece74e
12 N5cdd0646ab8046c0a8e2af2df72189ec
13 N69fc432a848740958229e6dca2aabd35
14 Naca648b914894d06a863d80349459dd6
15 Nda4bb7e36ccd41b388575a8595dc8059
16 Ne74def1e9b4941a78d860eb72eff6a4f
17 Ne81ddb6dc72d4888a5d1cdaec8045b06
18 Nfc871248c1ef49769b999c3dbd309318
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author N7df739322b0d4232857633ee239f691c
22 schema:citation sg:pub.10.1007/s00277-011-1253-9
23 sg:pub.10.1007/s00277-015-2349-4
24 sg:pub.10.1038/bmt.2013.185
25 sg:pub.10.1038/bmt.2015.297
26 sg:pub.10.1038/sj.bmt.1704784
27 sg:pub.10.1038/sj.bmt.1705965
28 https://app.dimensions.ai/details/publication/pub.1076834181
29 https://app.dimensions.ai/details/publication/pub.1083204471
30 https://doi.org/10.1001/jama.1993.03510010063030
31 https://doi.org/10.1046/j.1365-2141.2000.02196.x
32 https://doi.org/10.1080/10245330701214285
33 https://doi.org/10.1080/10428190701671051
34 https://doi.org/10.1097/moh.0b013e3283309647
35 https://doi.org/10.1111/ejh.12615
36 https://doi.org/10.1182/blood-2002-11-3615
37 https://doi.org/10.1182/blood-2003-03-0855
38 https://doi.org/10.1182/blood-2005-05-2004
39 https://doi.org/10.1182/blood-2005-10-4165
40 https://doi.org/10.1200/jco.1988.6.10.1562
41 https://doi.org/10.1200/jco.2002.12.049
42 https://doi.org/10.1200/jco.2005.07.061
43 https://doi.org/10.1200/jco.2009.23.3429
44 https://doi.org/10.1200/jco.2013.48.8114
45 https://doi.org/10.1200/jco.2015.62.7273
46 https://doi.org/10.3324/haematol.2012.070235
47 schema:datePublished 2017-03
48 schema:datePublishedReg 2017-03-01
49 schema:description The fludarabine, amsacrine, and cytarabine (FLAMSA)-reduced-intensity conditioning (RIC) protocol has been described to be effective in patients with high-risk and refractory acute myeloic leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (aSCT). To increase safety and tolerability of the conditioning, we previously reported the feasibility to substitute the TBI component by treosulfan in elderly AML patients. We now present long-term follow-up data on patients treated with FLAMSA/treosulfan compared to the original FLAMSA/4Gy TBI protocol. We retrospectively analyzed 130 consecutive patients with high-risk or relapsed AML after aSCT following FLAMSA conditioning at our center. Fifty-eight patients were treated with FLAMSA/treosulfan due to age and/or comorbidities. Seventy-two patients were treated with FLAMSA/TBI. Median age of patients treated with FLAMSA/treosulfan was 60 years compared to 46 years in those treated with FLAMSA/TBI. The cumulative incidence of a non-relapse mortality at 4 years was 28% in FLAMSA/treosulfan patients as compared to 13% in FLAMSA/TBI. Cumulative incidence of relapse was higher in patients treated with FLAMSA/TBI (46 vs. 32%). This difference was even more prominent for patients treated in blast persistence prior to transplant (relapse incidence 70% for TBI vs. 35% for treosulfan). The overall and relapse-free survival rates at 4 years were 47 and 41%, respectively, for patients treated with FLAMSA/TBI as compared to 43 and 40% in patients treated with FLAMSA/treosulfan. These data indicate an anti-leukemic activity by FLAMSA/treosulfan especially in patients with a blast persistence prior to transplant. Older age was an independent factor for a higher non-relapse mortality. Translating FLAMSA/treosulfan to younger patients, a lower non-relapse mortality, and an improved anti-leukemic activity might add up to improved overall survival. Randomized studies are required to demonstrate an improved efficacy of treosulfan- versus TBI-based FLAMSA conditioning.
50 schema:genre research_article
51 schema:inLanguage en
52 schema:isAccessibleForFree false
53 schema:isPartOf N819b25d022f64341be9a6e892e81f4d8
54 Nad3ef66e54fe44fd8b7cc1e09ba60f8b
55 sg:journal.1018247
56 schema:name Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML
57 schema:pagination 479-487
58 schema:productId N00c68287db544b3383ea03f6e194c71d
59 N0976e6d266604b0cb641ef4d0fe08d6b
60 N144c1707067e4b638e68df6cea3b7c51
61 N4716343b295a410ab608a3bf94f6e02f
62 N74d101c663eb485ab9a1376c526f31e2
63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007456209
64 https://doi.org/10.1007/s00277-016-2887-4
65 schema:sdDatePublished 2019-04-11T12:24
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher N1552f289892349de98e67f7f45ce619b
68 schema:url https://link.springer.com/10.1007%2Fs00277-016-2887-4
69 sgo:license sg:explorer/license/
70 sgo:sdDataset articles
71 rdf:type schema:ScholarlyArticle
72 N00c68287db544b3383ea03f6e194c71d schema:name readcube_id
73 schema:value 2383efb33993cdb76c2494692526325dd4575e739d3e99675078080540a7e675
74 rdf:type schema:PropertyValue
75 N0464975e77fe4ea6ac7076d3aadaf442 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Female
77 rdf:type schema:DefinedTerm
78 N058320180603484c8cde9a5d3bcade26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Retrospective Studies
80 rdf:type schema:DefinedTerm
81 N0909d8428c784616a553a25987db0184 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Leukemia, Myeloid, Acute
83 rdf:type schema:DefinedTerm
84 N0976e6d266604b0cb641ef4d0fe08d6b schema:name pubmed_id
85 schema:value 27909887
86 rdf:type schema:PropertyValue
87 N0c3763d7446b4e9b884646cba85ced89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Young Adult
89 rdf:type schema:DefinedTerm
90 N11e810deffa74474a1700f67065adb01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Treatment Outcome
92 rdf:type schema:DefinedTerm
93 N144c1707067e4b638e68df6cea3b7c51 schema:name doi
94 schema:value 10.1007/s00277-016-2887-4
95 rdf:type schema:PropertyValue
96 N1552f289892349de98e67f7f45ce619b schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 N34c72d37052d41e4a6493bd52cbd3891 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Busulfan
100 rdf:type schema:DefinedTerm
101 N3e480aa999424ee090aa8b5d5bbb5884 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Whole-Body Irradiation
103 rdf:type schema:DefinedTerm
104 N3ebfaf3943544722951328981cbc74bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Antineoplastic Agents, Alkylating
106 rdf:type schema:DefinedTerm
107 N46922b729f294be393912753ae1336bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Survival Rate
109 rdf:type schema:DefinedTerm
110 N4716343b295a410ab608a3bf94f6e02f schema:name nlm_unique_id
111 schema:value 9107334
112 rdf:type schema:PropertyValue
113 N4d421574c4114defb87e73f88aae0f70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Risk Factors
115 rdf:type schema:DefinedTerm
116 N5000720823d24080a2c8c44b78ece74e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Follow-Up Studies
118 rdf:type schema:DefinedTerm
119 N5be78bc3d4464d2195046a1eb717790f rdf:first sg:person.0776253454.97
120 rdf:rest N991090023fd04e78a682b5d71d9c7554
121 N5cdd0646ab8046c0a8e2af2df72189ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Transplantation, Homologous
123 rdf:type schema:DefinedTerm
124 N69fc432a848740958229e6dca2aabd35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Hematopoietic Stem Cell Transplantation
126 rdf:type schema:DefinedTerm
127 N74d101c663eb485ab9a1376c526f31e2 schema:name dimensions_id
128 schema:value pub.1007456209
129 rdf:type schema:PropertyValue
130 N7df739322b0d4232857633ee239f691c rdf:first sg:person.01060152106.45
131 rdf:rest Nc5c38d8d95644583b6072d304b73ab41
132 N819b25d022f64341be9a6e892e81f4d8 schema:issueNumber 3
133 rdf:type schema:PublicationIssue
134 N991090023fd04e78a682b5d71d9c7554 rdf:first sg:person.01167664514.20
135 rdf:rest Na84c0b6292c640788c998c5ecf823024
136 N9a2355a0e8cd4949a72563ef0e1cf159 rdf:first sg:person.01025161256.58
137 rdf:rest Nb897b5cf86f049b98085f04a7bee6691
138 N9d83c731238048579298d9babb248f13 rdf:first sg:person.0775410503.46
139 rdf:rest N5be78bc3d4464d2195046a1eb717790f
140 Na84c0b6292c640788c998c5ecf823024 rdf:first sg:person.014553451012.26
141 rdf:rest N9a2355a0e8cd4949a72563ef0e1cf159
142 Naca648b914894d06a863d80349459dd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Humans
144 rdf:type schema:DefinedTerm
145 Nad3ef66e54fe44fd8b7cc1e09ba60f8b schema:volumeNumber 96
146 rdf:type schema:PublicationVolume
147 Nb897b5cf86f049b98085f04a7bee6691 rdf:first sg:person.01312015730.26
148 rdf:rest Neb4b168fb4db42519d59b1b0ae6ddfc4
149 Nc5c38d8d95644583b6072d304b73ab41 rdf:first sg:person.01046626565.60
150 rdf:rest N9d83c731238048579298d9babb248f13
151 Nda4bb7e36ccd41b388575a8595dc8059 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Male
153 rdf:type schema:DefinedTerm
154 Ne74def1e9b4941a78d860eb72eff6a4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Aged
156 rdf:type schema:DefinedTerm
157 Ne81ddb6dc72d4888a5d1cdaec8045b06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Adult
159 rdf:type schema:DefinedTerm
160 Neb4b168fb4db42519d59b1b0ae6ddfc4 rdf:first sg:person.01126003571.55
161 rdf:rest rdf:nil
162 Nfc871248c1ef49769b999c3dbd309318 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Transplantation Conditioning
164 rdf:type schema:DefinedTerm
165 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
166 schema:name Medical and Health Sciences
167 rdf:type schema:DefinedTerm
168 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
169 schema:name Oncology and Carcinogenesis
170 rdf:type schema:DefinedTerm
171 sg:journal.1018247 schema:issn 1269-3286
172 1279-8509
173 schema:name Annals of Hematology
174 rdf:type schema:Periodical
175 sg:person.01025161256.58 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
176 schema:familyName Hallek
177 schema:givenName Michael
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025161256.58
179 rdf:type schema:Person
180 sg:person.01046626565.60 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
181 schema:familyName Herling
182 schema:givenName Marco
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046626565.60
184 rdf:type schema:Person
185 sg:person.01060152106.45 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
186 schema:familyName Holtick
187 schema:givenName Udo
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060152106.45
189 rdf:type schema:Person
190 sg:person.01126003571.55 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
191 schema:familyName Chemnitz
192 schema:givenName Jens M.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126003571.55
194 rdf:type schema:Person
195 sg:person.01167664514.20 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
196 schema:familyName Leitzke
197 schema:givenName Silke
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167664514.20
199 rdf:type schema:Person
200 sg:person.01312015730.26 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
201 schema:familyName Scheid
202 schema:givenName Christof
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312015730.26
204 rdf:type schema:Person
205 sg:person.014553451012.26 schema:affiliation https://www.grid.ac/institutes/grid.10388.32
206 schema:familyName Wolf
207 schema:givenName Dominik
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014553451012.26
209 rdf:type schema:Person
210 sg:person.0775410503.46 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
211 schema:familyName Pflug
212 schema:givenName Natali
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775410503.46
214 rdf:type schema:Person
215 sg:person.0776253454.97 schema:affiliation https://www.grid.ac/institutes/grid.6190.e
216 schema:familyName Chakupurakal
217 schema:givenName Geothy
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776253454.97
219 rdf:type schema:Person
220 sg:pub.10.1007/s00277-011-1253-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037372318
221 https://doi.org/10.1007/s00277-011-1253-9
222 rdf:type schema:CreativeWork
223 sg:pub.10.1007/s00277-015-2349-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005008575
224 https://doi.org/10.1007/s00277-015-2349-4
225 rdf:type schema:CreativeWork
226 sg:pub.10.1038/bmt.2013.185 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036134746
227 https://doi.org/10.1038/bmt.2013.185
228 rdf:type schema:CreativeWork
229 sg:pub.10.1038/bmt.2015.297 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000925323
230 https://doi.org/10.1038/bmt.2015.297
231 rdf:type schema:CreativeWork
232 sg:pub.10.1038/sj.bmt.1704784 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050128567
233 https://doi.org/10.1038/sj.bmt.1704784
234 rdf:type schema:CreativeWork
235 sg:pub.10.1038/sj.bmt.1705965 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035841647
236 https://doi.org/10.1038/sj.bmt.1705965
237 rdf:type schema:CreativeWork
238 https://app.dimensions.ai/details/publication/pub.1076834181 schema:CreativeWork
239 https://app.dimensions.ai/details/publication/pub.1083204471 schema:CreativeWork
240 https://doi.org/10.1001/jama.1993.03510010063030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008473572
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1046/j.1365-2141.2000.02196.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1056733260
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1080/10245330701214285 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058358190
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1080/10428190701671051 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006880760
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1097/moh.0b013e3283309647 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044469666
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1111/ejh.12615 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031702566
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1182/blood-2002-11-3615 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008819249
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1182/blood-2003-03-0855 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034662194
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1182/blood-2005-05-2004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027035706
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1182/blood-2005-10-4165 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002613179
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1200/jco.1988.6.10.1562 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079525316
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1200/jco.2002.12.049 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203203
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1200/jco.2005.07.061 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044565530
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1200/jco.2009.23.3429 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026375599
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1200/jco.2013.48.8114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018190408
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1200/jco.2015.62.7273 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016119976
271 rdf:type schema:CreativeWork
272 https://doi.org/10.3324/haematol.2012.070235 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025546715
273 rdf:type schema:CreativeWork
274 https://www.grid.ac/institutes/grid.10388.32 schema:alternateName University of Bonn
275 schema:name Department III of Internal Medicine, University of Bonn, Bonn, Germany
276 rdf:type schema:Organization
277 https://www.grid.ac/institutes/grid.6190.e schema:alternateName University of Cologne
278 schema:name BMT Program, Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50924, Köln, Germany
279 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...